|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
62,030,000 |
Market
Cap: |
1.03(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.48 - $21.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
11 |
Total Shares Sold |
274,520 |
293,400 |
293,400 |
298,772 |
Total Sell Value |
$4,804,928 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
Total People Sold |
5 |
5 |
5 |
5 |
Total Sell Transactions |
10 |
11 |
11 |
12 |
End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-04-04 |
4 |
AS |
$15.07 |
$799,148 |
D/D |
(51,395) |
0 |
|
-1% |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-04-04 |
4 |
OE |
$4.82 |
$204,850 |
D/D |
42,500 |
51,395 |
|
- |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-03-06 |
4 |
AS |
$21.50 |
$421,938 |
D/D |
(19,625) |
8,895 |
|
-18% |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-03-06 |
4 |
OE |
$10.15 |
$213,875 |
D/D |
19,625 |
28,520 |
|
- |
|
Karrels James |
SVP, CFO and Secretary |
|
2024-03-04 |
4 |
AS |
$20.50 |
$615,000 |
D/D |
(30,000) |
171,452 |
|
-15% |
|
Spitznagel Thomas |
Sr VP, Technical Ops |
|
2024-03-04 |
4 |
AS |
$20.00 |
$200,000 |
D/D |
(10,000) |
8,316 |
|
-15% |
|
Spitznagel Thomas |
Sr VP, Technical Ops |
|
2024-03-04 |
4 |
OE |
$11.50 |
$115,000 |
D/D |
10,000 |
18,316 |
|
- |
|
Risser Eric Blasius |
Chief Operating Officer |
|
2024-03-04 |
4 |
AS |
$19.63 |
$813,501 |
D/D |
(41,159) |
38,900 |
|
-15% |
|
Risser Eric Blasius |
Chief Operating Officer |
|
2024-03-04 |
4 |
OE |
$10.15 |
$152,250 |
D/D |
15,000 |
80,059 |
|
- |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-02-26 |
4 |
AS |
$17.22 |
$277,655 |
D/D |
(16,124) |
8,895 |
|
4% |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-02-22 |
4 |
D |
$17.11 |
$173,256 |
D/D |
(10,126) |
25,019 |
|
- |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,250 |
35,145 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2024-02-22 |
4 |
D |
$17.11 |
$160,252 |
D/D |
(9,366) |
100,892 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,125 |
110,258 |
|
- |
|
Risser Eric Blasius |
Chief Operating Officer |
|
2024-02-15 |
4 |
D |
$17.40 |
$102,295 |
D/D |
(5,879) |
65,059 |
|
- |
|
Risser Eric Blasius |
Chief Operating Officer |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,670 |
70,938 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2024-02-15 |
4 |
D |
$17.40 |
$102,155 |
D/D |
(5,871) |
82,133 |
|
- |
|
Bonvini Ezio |
Sr VP, Research & CSO |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,670 |
88,004 |
|
- |
|
Cilinski Lynn |
VP, Controller and Treasurer |
|
2024-02-15 |
4 |
D |
$17.40 |
$41,377 |
D/D |
(2,378) |
6,213 |
|
- |
|
Cilinski Lynn |
VP, Controller and Treasurer |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,668 |
8,591 |
|
- |
|
Eck Stephen L. |
Chief Medical Officer |
|
2024-02-15 |
4 |
D |
$17.40 |
$119,573 |
D/D |
(6,872) |
9,798 |
|
- |
|
Eck Stephen L. |
Chief Medical Officer |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,670 |
16,670 |
|
- |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-02-15 |
4 |
D |
$17.40 |
$77,273 |
D/D |
(4,441) |
8,895 |
|
- |
|
Peters Jeffrey Stuart |
Senior VP and General Counsel |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,336 |
13,336 |
|
- |
|
Karrels James |
SVP, CFO and Secretary |
|
2024-02-15 |
4 |
D |
$17.40 |
$92,690 |
D/D |
(5,327) |
201,452 |
|
- |
|
310 Records found
|
|
Page 1 of 13 |
|
|